Bioprocess optimization for purification of chimeric VLP displaying BVDV E2 antigens produced in yeast Hansenula polymorpha

Wetzel, David; Barbian, Andreas; Jenzelewski, Volker; Schembecker, Gerhard; Merz, J.; Piontek, Michael

doi:10.1016/j.jbiotec.2019.10.008

Cited by 14 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it may affect downstream applications because of the presence of the host protein. The eVLPs have been used to develop vaccines against viral diseases, such as the hantaan virus, hepatitis C virus (HCV), influenza A, and retroviruses ( Wetzel et al, 2019a ). These large eVLPs have a size greater than 100 nm, so there is a chance that they might aggregate at the site of injection and will not reach the lymph nodes that limit their application ( Keikha et al, 2021 ).…”

Section: Types Of Virus-like Particles Based On Structurementioning

confidence: 99%

“…Chimeric virus-like particles (cVLPs) are considered an effective tool for developing vaccines that provide broader, more powerful, and comprehensive protection against emerging infectious diseases ( Wetzel et al, 2019a ). The complex, multi-protein macrostructures contain epitopes of different viruses ( Latham and Galarza, 2001 ).…”

Section: Types Of Virus-like Particles Based On Structurementioning

confidence: 99%

See 1 more Smart Citation

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

Virus-like particles (VLPs) are nanostructures that possess diverse applications in therapeutics, immunization, and diagnostics. With the recent advancements in biomedical engineering technologies, commercially available VLP-based vaccines are being extensively used to combat infectious diseases, whereas many more are in different stages of development in clinical studies. Because of their desired characteristics in terms of efficacy, safety, and diversity, VLP-based approaches might become more recurrent in the years to come. However, some production and fabrication challenges must be addressed before VLP-based approaches can be widely used in therapeutics. This review offers insight into the recent VLP-based vaccines development, with an emphasis on their characteristics, expression systems, and potential applicability as ideal candidates to combat emerging virulent pathogens. Finally, the potential of VLP-based vaccine as viable and efficient immunizing agents to induce immunity against virulent infectious agents, including, SARS-CoV-2 and protein nanoparticle-based vaccines has been elaborated. Thus, VLP vaccines may serve as an effective alternative to conventional vaccine strategies in combating emerging infectious diseases.

show abstract

Section: Types Of Virus-like Particles Based On Structurementioning

confidence: 99%

Section: Types Of Virus-like Particles Based On Structurementioning

confidence: 99%

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover, VLPs-based vaccines received significant attention for their potential promise in developing effective and safe vaccines against influenza viruses [ 6 , 7 ]. Commercialized prophylactic VLPs-based vaccines have been developed, including baculovirus-derived papillomavirus VLPs vaccines against cervical cancer and hepatitis B virus VLPs vaccines against chronic hepatitis B virus infection [ 8 , 9 ], which support the development of additional baculovirus-derived vaccines. Influenza VLPs are a new generation of egg-independent candidate vaccines that encode genes for the three influenza virus proteins, hemagglutinin (HA) and neuraminidase (NA), along with the viral core protein matrix (M1) [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens

El-Husseiny¹,

Hagag²,

Pushko

et al. 2021

Vaccines

View full text Add to dashboard Cite

Highly pathogenic Avian Influenza (HPAI) viruses continue to cause severe economic losses in poultry species worldwide. HPAI virus of subtype H5N1 was reported in Egypt in 2006, and despite vaccination efforts, the virus has become endemic. The current study aims to evaluate the efficacy of a virus-like particle (VLP) based vaccine in vivo using specific pathogen-free (SPF) chickens. The vaccine was prepared from the HPAI H5N1 virus of clade 2.2.1.2 using the baculovirus expression system. The VLPs were quantitated and characterized, including electron microscopy. In addition, the protection level of the VLPs was evaluated by using two different regimens, including one dose and two-dose vaccinated groups, which gave up to 70% and 100% protection level, respectively. The results of this study emphasize the potential usefulness of the VLPs-based vaccine as an alternative vaccine candidate for the control of AIV infection in poultry.

show abstract

“…Subsequently, Capto™ Core 700, a commercially available chromatography resin based on beads bearing a ligand-activated core that entraps only molecules smaller than 700 kDa, was used for further enrichment of viral particles using an in-slurry approach. To date, Capto™ Core 700 chromatography has proven to be effective in purifying, among others, influenza A and B viruses [ 22 ], reovirus [ 19 ], respiratory syncytial virus [ 23 ], and virus-like particles [ 24 , 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

A Versatile Processing Workflow to Enable Pathogen Detection in Clinical Samples from Organs Using VIDISCA

et al. 2021

View full text Add to dashboard Cite

In recent years, refined molecular methods coupled with powerful high throughput sequencing technologies have increased the potential of virus discovery in clinical samples. However, host genetic material remains a complicating factor that interferes with discovery of novel viruses in solid tissue samples as the relative abundance of the virus material is low. Physical enrichment processing methods, although usually complicated, labor-intensive, and costly, have proven to be successful for improving sensitivity of virus detection in complex samples. In order to further increase detectability, we studied the application of fast and simple high-throughput virus enrichment methods on tissue homogenates. Probe sonication in high EDTA concentrations, organic extraction with Vertrel™ XF, or a combination of both, were applied prior to chromatography-like enrichment using Capto™ Core 700 resin, after which effects on virus detection sensitivity by the VIDISCA method were determined. Sonication in the presence of high concentrations of EDTA showed the best performance with an increased proportion of viral reads, up to 9.4 times, yet minimal effect on the host background signal. When this sonication procedure in high EDTA concentrations was followed by organic extraction with Vertrel™ XF and two rounds of core bead chromatography enrichment, an increase up to 10.5 times in the proportion of viral reads in the processed samples was achieved, with reduction of host background sequencing. We present a simple and semi-high-throughput method that can be used to enrich homogenized tissue samples for viral reads.

show abstract

Bioprocess optimization for purification of chimeric VLP displaying BVDV E2 antigens produced in yeast Hansenula polymorpha

Cited by 14 publications

References 26 publications

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens

A Versatile Processing Workflow to Enable Pathogen Detection in Clinical Samples from Organs Using VIDISCA

Contact Info

Product

Resources

About